The Long Island Parkinson's Disease Center

描述(申请人提供)：帕金森病(PD)是一种常见的退行性神经系统疾病，影响大约100万美国人。在过去的十年里，帕金森病的治疗和管理的进步越来越需要普通神经科医生向运动障碍专家寻求建议，以优化帕金森病患者的护理。具体地说，运动障碍专家现在正在管理正在考虑和正在接受帕金森病手术治疗(例如，脑深部刺激[DBS])的患者，以及早期和晚期帕金森病的常规临床治疗。此外，随着对帕金森病病理生理学认识的进步，减缓帕金森病病程的新策略正在出现。随着这些疗法已经开始进入临床试验，患者已经并可能继续主要通过PD中心获得这些试验。 我们在纽约州长岛或附近拥有PD专家网络，他们结合了PD管理方面的实践经验、丰富的临床试验经验以及与开发用于评估PD治疗的成像方法相关的临床研究成果。长岛地区的总人口约为500万，但我们的集水区还包括曼哈顿、皇后区、布鲁克林和斯塔滕岛的部分地区。我们的运动障碍中心目前跟踪了大约2500名PD患者，我们参与或领导了20项PD临床试验；总共有50名受试者参加了Net-PD试验。凭借我们的PD临床试验和研究经验以及非常广泛的人群基础，我们处于独特的地位，可以继续成功地参与PD的大规模简单神经保护临床试验。到目前为止，我们非常成功地招募了科目，这支持了这一点。

DESCRIPTION (provided by applicant): Parkinson's disease (PD) is a common degenerative neurological disease, affecting approximately 1 million Americans. Advances in the treatment and management of PD over the past ten years have increasingly required general neurologists to seek advice from Movement Disorders specialists in order to optimize PD patient care. Specifically, Movement Disorders specialists are now managing patients considering and undergoing surgical treatments for PD (e.g. deep brain stimulation [DBS]), as well as routine clinical management for both early and late stage PD. Furthermore, with advances in the understanding of the pathophysiology of PD, new strategies for slowing the course of PD are emerging. As these therapies have begun to move to clinical trials, patient access to these trials has been and will likely continue to be primarily through PD centers. We have a network of PD specialists in or near Long Island, NY with a combination of practical experience in the management of PD, extensive clinical trial experience, and clinical research excellence related to the development of imaging methods for assessing therapies for PD. The Long Island region comprises a general population of approximately 5 million people, but our catchment area also includes parts of Manhattan, Queens, Brooklyn, and Staten Island. Our Movement Disorders Center currently follows approximately 2,500 PD patients, and we have participated or led >20 PD clinical trials; in total, we have enrolled 50 subjects in the NET-PD trials. With our combination of PD clinical trial and research experience and a very broad population base, we are uniquely positioned to continue participating successfully in the large-scale simple neuroprotective clinical trial for PD. This is supported by our highly successful recruitment of subjects to date.